Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Roche says closed Chinese cities hinder virus diagnostics test deliveries

Published 30/01/2020, 10:28
Roche says closed Chinese cities hinder virus diagnostics test deliveries
ROG
-
GILD
-

By Paul Arnold

BASEL (Reuters) - Swiss drugmaker Roche (S:ROG) is struggling to deliver diagnostic tests for the coronavirus to large Chinese cities after Communist Party rulers halted people from entering and leaving in a bid to halt the spreading outbreak.

"Getting the goods to hospitals has been a real challenge," Roche diagnostics boss Thomas Schinecker told reporters on Thursday.

Chief Executive Severin Schwan said Roche was the first company to supply tests to diagnose the virus, thought to have originated in a food market in the city of Wuhan with about 11 million people, and has now seen thousands of cases and at least 170 deaths in China.

The Swiss drugmaker was able to call on some of its experience in helping identify the SARS virus, a previous outbreak that originated in China, two decades ago.

Roche does not anticipate rising business from its coronavirus tests, as they had to be delivered quickly, making any negotiations over price impossible. To start, Schwan said, the company just gave the tests away for free.

"You can forget this as a business opportunity," he said, adding that the company had been able to build up its goodwill with public health authorities.

Roche, the biggest maker of cancer drugs, is also the largest manufacturer of diagnostic equipment for identifying diseases.

Roche does have anti-viral drugs, including its flu medicine Xofluza, approved in 2018. But the company's main pharmaceuticals division head, Bill Anderson, said that medicine is specifically designed to combat the spread of seasonal flu, and is unlikely to have an impact on the coronavirus.

For that, drugs that are effective against HIV or AIDS may offer some opportunity, he said. Gilead Sciences (O:GILD) is also reviewing its experimental Ebola drug for potential use against the coronavirus.

Countries began isolating hundreds of citizens evacuated from Wuhan on Thursday to stop the spread of an epidemic as worry about the impact on the world's second-biggest economy rattled markets.

India became the latest country to report a case - a student of Wuhan University - while anger and fear brought protests in South Korea and threats of strikes in Hong Kong.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.